Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020

$3,495.00

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies.

Publication date
October 2020
Number of pages
450+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2062

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies.

 

This report provides details of the latest Co-development agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of Co-development agreements from 2014 to 2020.

 

There is an increasing willingness for parties to enter co-development deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

 

Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

 

There are mainly two forms of co-development deals; Either the parties agree on a certain division of ownership, or decide that one party gets the rights to commercialise the drug in a certain geographical area, and the other side gets the other geographical area rights. Typically, the ownership division applies when it is likely that the project will be licensed at a later point in time. The geographical split usually applies when the two companies are determined to commercialise the drug themselves.

 

Another reason for co-development deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of Co-development deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual Co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of Co-development dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in Co-development as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of Co-development deals. The chapter includes numerous case studies to enable understanding of both pure Co-development deals and multicomponent deals where Co-development forms a part.

 

Chapter 4 provides a review of the leading Co-development deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a comprehensive listing of the top 25 most active Co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

 

Chapter 6 provides a comprehensive review of co-development financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

 

Chapter 7 provides a comprehensive and detailed review of Co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Co-development deal.

 

The appendices to the report includes a comprehensive listing of all Co-development deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous table and figures that illustrate the trends and activities in Co-development dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about Co-development alliances.

 

Key benefits

 

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of co-development partnering deal trends since 2014
  • Analysis of the structure of co-development agreements with numerous real life case studies
  • Comprehensive listing of all co-development deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual co-development contracts entered into by the world’s leading life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a co-development agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading life science companies worldwide.         

 

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 includes:

 

  • Trends in co-development dealmaking in the biopharma industry since 2014
  • Analysis of co-development deal structure
  • Case studies of real-life co-development deals
  • Comprehensive listing of co-development deals since 2014
  • Access to co-development contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading co-development deals by value since 2014
  • Most active co-development dealmakers since 2014
  • The leading co-development partnering resources

 

In Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

 

The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive access to available contract documents for co-development deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020 provides the reader with the following key benefits:

 

  • In-depth understanding of co-development deal trends since 2014
  • Analysis of the structure of co-development agreements with numerous real life case studies
  • Comprehensive listing of all co-development deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual co-development contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a co-development agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Co-development dealmaking

 

2.1. Introduction

2.2. Definition of co-development deals

2.3. Success factors for co-development deals

2.4. When co-development can be useful

2.5. Attributes of co-development deals

2.6. Aligning partners to make the co-development work

2.7. Trends in Co-development deals since 2014

2.7.1. Co-development dealmaking by year, 2014 to 2020

2.7.2. Co-development dealmaking by phase of development, 2014 to 2020

2.7.3. Co-development dealmaking by industry sector, 2014 to 2020

2.7.4. Co-development dealmaking by therapy area, 2014 to 2020

2.7.5. Co-development dealmaking by technology type, 2014 to 2020

2.7.6. Co-development dealmaking by most active company, 2014 to 2020

2.8. Option to co-develop

2.9. The future of co-development deals

 

Chapter 3 – Overview of Co-development deal structure

 

3.1. Introduction

3.2. Pure versus multi-component co-development deals

3.3. Pure co-development agreement structure

3.3.1. Example co-development agreements

3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine

3.3.1.b. Case study 2: UniQure - Chiesi

 

Chapter 4 – Leading Co-development deals

 

4.1. Introduction

4.2. Top Co-development deals by value

 

Chapter 5 – Top 25 most active Co-development dealmakers

 

5.1. Introduction

5.2. Top 25 most active Co-development dealmakers

 

Chapter 6 – Co-development deal term financials

 

6.1. Introduction

6.2. Co-development partnering headline values

6.3. Co-development deal upfront payments

6.4. Co-development deal milestone payments

6.5. Co-development royalty rates

 

Chapter 7 – Co-development deals including contracts directory

 

7.1. Introduction

7.2. Co-development deals with contracts 2014 to 2020

 

Appendices

 

Appendix 1 – Co-development dealmaking by companies A-Z

Appendix 2 – Co-development dealmaking by industry sector

Appendix 3 – Co-development dealmaking by stage of development

Appendix 4 – Co-development dealmaking by therapy area

Appendix 5 – Co-development dealmaking by technology

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

TABLE OF FIGURES

 

Figure 1: Definition of co-development

Figure 2: Situations where co-development can prove useful

Figure 3: Key components of a co-development deal

Figure 4: Issues in implementing co-development agreements

Figure 5: Trends in Co-development deal announcements, 2014 to 2020

Figure 6: Co-development deals signed at each phase of development, 2014 to 2020

Figure 7: Co-development deals by industry sector, 2014 to 2020

Figure 8: Co-development deals by therapy area, 2014 to 2020

Figure 9: Co-development deals by technology type, 2014 to 2020

Figure 10: Top 25 most active co-development dealmakers, 2014 to 2020

Figure 11: Co-development agreements – what should a contract include?

Figure 12: Components of the co-development deal structure

Figure 13: Top co-development deals by value 2014 to 2020

Figure 14: Most active Co-development dealmakers 2014 to 2020

Figure 15: Co-development deals with a headline value

Figure 16: Co-development deals with an upfront value

Figure 17: Co-development deals with a milestone value

Figure 18: Co-development deals with a royalty rate value

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 3B Pharmaceuticals, 3D-Micromac, 3DMed, 3D Systems, 10X Genomics, A*STAR Agency for Science, Technology and Research, A*STAR Institute of Microelectronics (IME), A2A Pharmaceuticals, Abbvie, AbCellera, ABL Bio, Abpro, Academy of Military Medical Sciences (China), Accellix, Accent Therapeutics, Accord Healthcare, AccuGenomics, ACEA Biosciences, AC Immune, Acoustic MedSystems, Adaptimmune, Aduro BioTech, Advaxis, Adventist Health, Adventus Ventures, Aerolase, Affibody, Affimed Therapeutics, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, AiLife Diagnostics, Ajinomoto, Akcea Therapeutics, Albany Molecular Research, Alexion Pharmaceuticals, Algenex, Align Technology, Alkem Laboratories, Allegheny Technologies, Allele Biotechnology and Pharmaceuticals, Alligator Bioscience, Allotex, Alnylam Pharmaceuticals, Alphaeon, Alphamab Biopharmaceuticals, Alteogen, Alternavida, Altor BioScience, Altos Group, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, Ambrx, Amedica, Amerigen Pharmaceuticals, Amgen, Amplifire, Amyris, AnaptysBio, AnchorDx, AnGes MG, Angionetics, Annoroad, Ansell, Anteo Diagnostics, Anthem, AntiOp, AOP Orphan Pharmaceuticals, Apobiologix, Aptar Pharma, Aptevo Therapeutics, Aquestive Therapeutics, Aranda Pharma, ARaymondlife, Arbele, Arbutus, Arcturus Therapeutics, Arcus Biosciences, Areva Med, Ariad Pharmaceuticals, Arno Therapeutics (inactive since 2017), Artes Biotechnology, Asahi Intecc, Ascenion, Ascensia Diabetes Care, Aspen Imaging Healthcare, Astellas Pharma, AstraZeneca, Atomwise, Atropos Therapeutics, AutoGenomics, Autotelic BIO, Avactis Biosciences, Avalanche Biotechnologies, Avalon GloboCare, Avellino Labs, Aviragen Therapeutics, Axela, AXIM Biotechnologies, Azitra, Azos Bio, Banyan Biomarkers, BASF, Battelle, Bayer, Bayer Healthcare, Baylor College of Medicine, BD Biosciences, BehaVR, BeiGene, Beijing Sun-Novo Pharmaceutical Research, Berry Genomics, Betta Pharmaceuticals, BGI Americas, Biedermann Motech, Bio-Rad Laboratories, Bio-Techne, BioAtla, BioCanna Healthcare, Biocept, BioComo, Biocon, Biodextris, BioGemex, Biogen, BioInvent, BioLabs, BioLegend, BiolineRX, BIOMEDX Group, bioMerieux, BioMotiv, BioNano Genomics, Bionpharma, BioNTech, BioPontis Alliance, BioSerenity, Biostar Pharmaceuticals, BioSun Pharmed, Bioventus, Bird Foundation, Blake Insomnia Therapeutics, Blanchette Rockefeller Neurosciences Institute, Bluebird Bio, Blueprint Medicines, BodyLogicMD, Boehringer Ingelheim, BoneSupport, Boreal Genomics, Boston Scientific, Breathe ECig, Bridge Biotherapeutics, Brigham and Women's Hospital, Bristol-Myers Squibb, Broad Institute, Bruker, Bruker Energy & Supercon Technologies (BEST), Burnet Institute, c-LEcta, Cactus Semiconductor, California Institute for Biomedical Research, Cambrooke Therapeutics, Can-Fite BioPharma, Cancer Genetics, Cancer Prevention Pharmaceuticals, Cancer Research Technology, CannaSoul Analytics, Cannassure Therapeutics, CannScience Innovations, Capsule Tech, Carbios, Cardiovascular Systems, CBT Pharmaceuticals, CEA-Leti, Celgene, Cellastra, Cellectis, Cellgen Diagnostics, Celltrion, Cellular Biomedicine, Celon Pharma, Censa Pharmaceuticals, Center for Connected Health, Center for Sensorimotor Neural Engineering, Central Institute for Experimental Animals, Centre for Drug Research and Development (CDRD), Centre for Imaging Technology Commercialization, Cerenis Therapeutics, Cerulean Pharma, Changzhou Le Sun Pharmaceuticals, Charles River Laboratories, Cheil Pharm, ChemDiv, Chi-Med, China National Biotech Group (CNBG), Chinese Academy of Sciences, Chiome Bioscience, ChromaDex, ChroMedX, Cidara Therapeutics, CimCure, Cipla, Ciron Drugs & Pharmaceuticals, Cleveland Clinic, Clevexel Pharma, Clinical Study Support, Codagenix, Coeptis Pharmaceuticals, College of Life Science of Northwest University, Collplant, Complement Pharma, Conductive Technologies, Confluence Pharmaceuticals, Conkwest, Context Therapeutics, Cosmo Pharmaceuticals, Covestro, CRISPR Therapeutics, Crystal Bioscience, CrystalGenomics, CSL, CSPC Pharmaceutical Group, CureVac, CutisPharma, Cygnus, Cytokinetics, CytomX Therapeutics, Dabur, Daewoong Pharmaceutical, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dako, Dalton Pharma Services, Dance Biopharm, DaRui Biotech, Deciphex, Decision Diagnostics, Definiens, Denali Therapeutics, Department of Defense, Department of Health and Human Services, DePuy, Dermavant Sciences, Dexcel Pharma, Dicerna Pharmaceuticals, DigiLab, Dilafor, Dilaforette, DNAnexus, Dr. Reddy's Laboratories, Dynavax Technologies, Ecole Polytechnique Federale de Lausanne, EdeniQ, Eisai, Elekta, Elektrofi, ElevateBio, Eli Lilly, Elite Pharmaceuticals, Elpis Biomed, Em-Tec, Emergent BioSolutions, Enigma Biomedical, Entasis Therapeutics, Enterome Bioscience, Ergomed, Especificos Stendhal, Essex Bio-Technology, Estee Lauder, Evercyte, Evidera, Evolva, Evosep, Evotec, EVQLV, Evvivax, Excelra, Exosome, Eybna Technologies, Fabric Genomics, Farmacore Biotechnology, Fate Therapeutics, Ferrer International, Firebrand Therapeutics, Flowerkist, FlowJo, Fluxion Biosciences, Fosun Pharmaceutical, Foundation Medicine, Fuzionaire Radioisotope Technologies, G2 Speech, GB Sciences, Gedeon Richter, GE Healthcare, Genea Biomedx, Genentech, Generex Biotechnology, Genethon, Genmab, Genomas, Genome Institute of Singapore, Genomic Testing Cooperative, Genomoncology, Genoptix, GensKey Medical Technology, Genzyme, Georgia State University Research Foundation (GSURF), Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Global Antibiotic Research and Development Partnership, Global Bio-chem Technology Group, Global Dx, GMSbiotech, Government of Canada, Great Bay Bio, Greiner Bio-One, GTEC Holdings, Guangzhou Boji Medical Biotechnological, Guerbet, Guilin Pharmaceutical, H.M. Pharma Consultancy, H3 Biomedicine, Hainan Sihuan Pharmaceutical, HalioDx, HaloVax, Hangzhou Joinstar Biomedical Technology, Hanmi Pharmaceutical, Happify Health, Harbour Antibodies, Harvard University, HCD Research, HD Biosciences, HealthCore, Heartflow, HEC Pharm, Henlius Biotech, Hereditary Neuropathy Foundation, Hitachi Chemical, Hitachi High-Technologies Corporation, Hollister Biosciences, Horizon Discovery, Hoth Therapeutics, HTC ChemRar, Huami, Hufeland Klinikum, Hummingbird Bioscience, I-Dante, I-mab, IBA, IBC Generium, iBio, IBM Watson Health, Icagen, IDbyDNA, Idorsia, Illumina, Immatics Biotechnologies, ImmBio, Immune Design, ImmunityBio, Immunocore, Impression Healthcare, Imricor Medical Systems, Incyte, InDi Molecular, Infinity Pharmaceuticals, Innate Pharma, inno-train Diagnostik, Innovent Biologics, Inova Genomics Laboratory, Inovio Pharmaceuticals, Insitro, InstantLabs, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute of Cancer Research, Institute of Microchemical Technology, Institut Gustave Roussy, Institut Pasteur, Intabio, Integrated Cannabis Company, IntelGenx, International Flavors and Fragrances, Intravacc, Intuitive Surgical, InventisBio, inviCRO, Ionis Pharmaceuticals, iPharma, Ipsen, ISIS Innovation, Isomerase Therapeutics, Jabez Pharma, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, JCR Pharmaceuticals, Jeffrey Modell Foundation, JETA Molecular, Jiangsu NHWA Pharmaceutical, Johns Hopkins University, Johnson & Johnson Innovation, Juno Therapeutics, Junshi Biosciences, JustRight Surgical, Kaken Pharmaceutical, Kalos Therapeutics, Kane Biotech, Klaria, Kleo Pharmaceuticals, Kyowa Hakko Kirin, Lannett, Laxai Pharma, Lead Discovery Center, Lee's Pharmaceutical, Leica Biosystems, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LifeLink Foundation, LifeLiver, LifeQ, LineaRx, Lipidor, Livzon Pharmaceutical, LogicNets, Loreal, Louisiana State University, Loxo Oncology, LTS Lohmann Therapie-Systeme, Lupin Limited, Luye Pharma Group, Lyell Immunopharma, Lygos, Macrogen, MagForce, MAKScientific, Mallinckrodt Pharmaceuticals, MangoGen Pharma, Marina Biotech, Marshall Institute for Interdisciplinary Research, Marshall University, Masimo, Massachusetts General Hospital, MaSTherCell, Max-Delbruck Center for Molecular Medicine, Mayo Clinic, Mazor Robotics, McCall MacBain Foundation, MD Anderson Cancer Center, MediciNova, Medidata Solutions, Medigen Biotechnology, Medigen Vaccine Biologics, MedImmune, Medtronic, MEI Pharma, Melinta Therapeutics, Menarini, Mercachem, Merck and Co, Merck KGaA, Merck Serono, Meridian Laboratories, Mersana Therapeutics, Merus, Merz, MetP Pharma, Mie University, Mikrogen, Millennium, Minerva Neurosciences, Mirati Therapeutics, MiRTLE Medical, Mission Health, Mochida Pharmaceutical, Moderna Therapeutics, Molecular Targeting Technologies, Molecular Templates, Molnlycke Health Care, Mologen, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, MorphoSys, Mount Sinai Medical Center, MRI Interventions, Mundipharma, Mundo Sano, Mylan Pharmaceuticals, MyLife Technologies, MYOS RENS Technology, Nanion, Nanjing King-friend Biochemical Pharmaceutical, Nankai Hospital, Nanommune, NanoSmart Pharmaceuticals, NanoString Technologies, NantKwest, NantPharma, Natera, National Cancer Institute, National Healthcare Services (NHS), National Health Research Institutes, National Immunobiological Company, National Institutes of Health, Navitor Pharmaceuticals, Ncardia, NEC, Nektar Therapeutics, Neptune Technologies & Bioressources, Neptune Wellness Solutions, NeuClone, Neuraly, Neurocrine Biosciences, Neuro France Implants, Neurotrope BioScience, NeuroVive Pharmaceutical, Newsoara Biopharma, NGM Biopharmaceuticals, Ningbo Menovo Pharmaceutical, Nipro Corporation, Noile-Immune Biotech, Noramco, Novartis, NovImmune, Novogene, Novoheart, Novo Nordisk, Novozymes, NTT Medical Center Tokyo, Nuclea Biotechnologies, Nuevolution, Numab, Nurix, NutriQuest, NuVasive, Ocugen, Ohio State University, Olympus, Oncologie, Oncology Pharma, One BioMed, OnFace, Ono Pharmaceutical, OpGen, OPKO Health, Opocrin S.p.A, Optum, Oregon Health Sciences University, Orgenesis, Ori Biotech, Orion, Orthocell, Osaka University, OSE Immunotherapeutics, Otsuka, Oxford BioMedica, Pacific Biosciences, PACT Pharma, Pairnomix, Palatin Technologies, Pall Corporation, Panasonic Healthcare, Par Pharmaceutical, PathGroup, PDS Biotechnology, Pebble Labs, Pep Therapy, PeptiDream, Perlara, Personal Genome Diagnostics, Pfizer, PharmaCyte Biotech, Pharma Tech Solutions, PhaseBio Pharmaceuticals, Phillips-Medisize, PhoreMost, PhosImmune, PhysIOL, Pieris, Pierre Fabre, Planet Wheeler Foundation, Praj Industries, Precision NanoSystems, Premier Inc, PreventionGenetics, Procter & Gamble, Profound Medical, Promethera Biosciences, Prometic Life Sciences, Promore Pharma, Propeller Health, Protagen, Protea Biosciences, Protein Metrics, Protein Sciences, Provention Bio, Pulmatrix, Purdue Pharma, Pure MHC, Pure Protein, Purolite, Qiagen, Qilu Pharmaceutical, Qualcomm, Quark Pharmaceuticals, Radiomedix, Rainbow Medical, RainDance Technologies, Rambam Medical Center, ReadSense Genomic Center, Recipharm, Reckitt Benckiser, RedHill Biopharma, Redlen Technologies, Regeneron Pharmaceuticals, Rennovia, Replicel Life Sciences, RespireRx Pharmaceuticals, Response Biomedical, Retrophin, RightEye, Roche, Roivant Sciences, RoosterBio, Rosetta Genomics, Royal Philips Electronics, Sajo Consulting, Salus Pharma, SanBio, Sandoz, Sanofi, Sanofi-Pasteur, Santen Pharmaceutical, Sarah Cannon Research Institute, Sarepta Therapeutics, Sartorius Stedim Biotech, SBRI Healthcare, Scandinavian Health, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, Scienion, Sciex, ScinoPharm Taiwan, SCM Pharma, Scottish Enterprise, Seattle Genetics, Secarna Pharmaceuticals, Seegene, Seipasa, Selvita, Semtech, SENSANALYSIS, Sentieon, Sentinel Oncology, Seracare Life Sciences, Serum Institute of India, SFJ Pharmaceuticals, Shaanxi Research Institution of Chinese Traditional Medicines, Shandong Luoxin Pharma, Shanxi Yabao Pharmaceutical Distribution, Siemens Healthcare, Siemens Healthineers, Sigma-Aldrich, Simcere Pharmaceuticals, Sinergium Biotech, Singulex, Sino Biological, Sirenas, SiSaf, SK Chemicals, SkylineDX, Smartwise, Soitec, Sonova, Sorrento Therapeutics, Spineguard, STADA Arzneimittel, Starpharma, Stealth Therapeutics, StemoniX, Stempeutics, Stockton Group, Stora Enso, Strand Life Sciences, StrideBio, Striiv, SunGen, Sunnybrook Health Sciences Centre, Sunny Pharmtech, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Swedish Bactiguard, Swift Biosciences, Synchronous Health, Synergetics, Synpromics, Synthonics, Tactical Relief, TaiwanBio Therapeutics, TaiwanJ Pharmaceuticals, Takeda Pharmaceutical, Takis Biotech, Tangible Science, Tango Therapeutics, Tarrex Biopharma, Tarveda Therapeutics, Tauriga Sciences, Tavotek Biotherapeutics, Taxus Cardium Pharmaceuticals, TC BioPharm, Tecan, Teijin, Tesaro, Tetra Bio-Pharma, Texas A&M University, TG Therapeutics, Therapyx, Theravance, Therawis Diagnostics, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, Tillotts Pharma, Tilray, Tissue Analytics, Tobii Technology, TOMA Biosciences, Torii Pharmaceutical, Toronto Innovation Acceleration Partners, Torrey Pines Investment, Transgene, Transgenomic, Translational Software, Transplant Genomics, Treeway, Treventis, TrovaGene, Trovita Health Science, Turnstone Biologics, Twist Bioscience, Ubic, UbiQ, UCB, UGISense, Ultivue, Ultragenyx Pharmaceuticals, Uni-Bio Science, UniQure, United Therapeutics, Universal Cells, University Hospital of Leuven, University of Bonn, University of Copenhagen, University of Guelph, University of Montreal, University of North Texas, University of Ottawa, University of Sydney, Univo Pharmaceuticals, Vaccitech, Valent Biosciences, Validogen, Valneva, Vanderbilt-Ingram Cancer Center, Vasomune Therapeutics, Vaximm, VeChain, Vect-Horus, Velabs Therapeutics, VenatoRx, Ventana Medical Systems, Vertex Pharmaceuticals, Vical, Vici Health Sciences, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vinnova, Virbac, Vir Biotechnology, Visualant, Vium, vivoPharm, Voltron Therapeutics, Voluntis, VSP Optics, WAVE Life Sciences, Weill Cornell Medical College, Wellcome Trust, WellDoc, Willow Biosciences, Worthington Biochemical Corporation, WuXi Biologics, X4 Pharmaceuticals, Xbrane Bioscience, Xencor, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xortx Therapeutics, Xylonix, Yabao Pharmaceutical, Yale University, Yisheng Biopharma, YOFOTO (China) Health Industry, Yonsei University Severance Hospital, Yuhan Corporation, Zavation, Zebra Medical Vision, Zhejiang Hisun Pharmaceutical, Zivo Bioscience, Zylo Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.